FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800280019> ?p ?o ?g. }

• W2800280019 endingPage "339" @default.
• W2800280019 startingPage "329" @default.
• W2800280019 abstract "<b><i>Objectives:</i></b> To investigate the clinical efficacy and tolerability of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> A total of 90 patients with advanced HCC, Child-Pugh class A–B7 cirrhosis, and no prior systemic therapy were randomly assigned (1: 1) to receive either 10 mg/kg B intravenously every 14 days and 150 mg E orally daily (<i>n</i> = 47) (B+E) or 400 mg S orally twice daily (<i>n</i> = 43). The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1), time to progression, and safety and tolerability. <b><i>Results:</i></b> The median OS was 8.55 months (95% CI: 7.00–13.9) for patients treated with B+E and 8.55 months (95% CI: 5.69–12.2) for patients receiving S. The hazard ratio (HR) for OS was 0.92 (95% CI: 0.57–1.47). The median EFS was 4.37 months (95% CI: 2.99–7.36) for patients receiving B+E and 2.76 months (95% CI: 1.84–4.80) for patients receiving S. The HR for EFS was 0.67 (95% CI: 0.42–1.07; <i>p</i> = 0.09), favoring B+E over S. When OS was assessed among patients who were Child-Pugh class A, the median OS was 11.4 months (95% CI: 7.5–15.7) for patients treated with B+E (<i>n</i> = 39) and 10.26 months (95% CI: 5.9–13.0) for patients treated with S (<i>n</i> = 38) (HR = 0.88; 95% CI: 0.53–1.46). <b><i>Conclusions:</i></b> There was no difference in efficacy between the B+E and S arms, although the safety and tolerability profile tended to favor B+E over S based on competing risk analysis." @default.
• W2800280019 created "2018-05-17" @default.
• W2800280019 creator A5005254288 @default.
• W2800280019 creator A5006872615 @default.
• W2800280019 creator A5007159753 @default.
• W2800280019 creator A5008358023 @default.
• W2800280019 creator A5013744957 @default.
• W2800280019 creator A5028472820 @default.
• W2800280019 creator A5029296725 @default.
• W2800280019 creator A5039313243 @default.
• W2800280019 creator A5047736184 @default.
• W2800280019 creator A5056125807 @default.
• W2800280019 creator A5063294358 @default.
• W2800280019 creator A5070748396 @default.
• W2800280019 creator A5084427458 @default.
• W2800280019 date "2018-01-01" @default.
• W2800280019 modified "2023-10-17" @default.
• W2800280019 title "A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma" @default.
• W2800280019 cites W1524776082 @default.
• W2800280019 cites W1961621350 @default.
• W2800280019 cites W1963653782 @default.
• W2800280019 cites W1971837077 @default.
• W2800280019 cites W1974342793 @default.
• W2800280019 cites W1979465904 @default.
• W2800280019 cites W1984632950 @default.
• W2800280019 cites W1986817171 @default.
• W2800280019 cites W1988631826 @default.
• W2800280019 cites W1989892577 @default.
• W2800280019 cites W1990303771 @default.
• W2800280019 cites W2001614274 @default.
• W2800280019 cites W2005129328 @default.
• W2800280019 cites W2006916640 @default.
• W2800280019 cites W2007362038 @default.
• W2800280019 cites W2008206360 @default.
• W2800280019 cites W2011582582 @default.
• W2800280019 cites W2019607817 @default.
• W2800280019 cites W2023459073 @default.
• W2800280019 cites W2023895580 @default.
• W2800280019 cites W2028525116 @default.
• W2800280019 cites W2032743024 @default.
• W2800280019 cites W2038625523 @default.
• W2800280019 cites W2045380897 @default.
• W2800280019 cites W2046000826 @default.
• W2800280019 cites W2047256604 @default.
• W2800280019 cites W2051684210 @default.
• W2800280019 cites W2051745191 @default.
• W2800280019 cites W2055590215 @default.
• W2800280019 cites W2058451329 @default.
• W2800280019 cites W2058887247 @default.
• W2800280019 cites W2059026940 @default.
• W2800280019 cites W2059320976 @default.
• W2800280019 cites W2060003767 @default.
• W2800280019 cites W2060123467 @default.
• W2800280019 cites W2063503700 @default.
• W2800280019 cites W2064949041 @default.
• W2800280019 cites W2066954468 @default.
• W2800280019 cites W2070396671 @default.
• W2800280019 cites W2071058106 @default.
• W2800280019 cites W2072574560 @default.
• W2800280019 cites W2074849180 @default.
• W2800280019 cites W2077203862 @default.
• W2800280019 cites W2080992186 @default.
• W2800280019 cites W2086702949 @default.
• W2800280019 cites W2087684145 @default.
• W2800280019 cites W2089298112 @default.
• W2800280019 cites W2089590075 @default.
• W2800280019 cites W2089783561 @default.
• W2800280019 cites W2095839230 @default.
• W2800280019 cites W2102960214 @default.
• W2800280019 cites W2114565983 @default.
• W2800280019 cites W2119242310 @default.
• W2800280019 cites W2119823629 @default.
• W2800280019 cites W2120967735 @default.
• W2800280019 cites W2122044186 @default.
• W2800280019 cites W2131047627 @default.
• W2800280019 cites W2143385760 @default.
• W2800280019 cites W2154533573 @default.
• W2800280019 cites W2158207366 @default.
• W2800280019 cites W2163271339 @default.
• W2800280019 cites W2166973314 @default.
• W2800280019 cites W2170655985 @default.
• W2800280019 cites W2199933644 @default.
• W2800280019 cites W2248378842 @default.
• W2800280019 cites W2399380240 @default.
• W2800280019 cites W2408646082 @default.
• W2800280019 cites W2413133079 @default.
• W2800280019 cites W2416771752 @default.
• W2800280019 cites W2467480021 @default.
• W2800280019 cites W2519468163 @default.
• W2800280019 cites W2560499218 @default.
• W2800280019 cites W2570618306 @default.
• W2800280019 cites W2591717879 @default.
• W2800280019 cites W2595391283 @default.
• W2800280019 cites W4236098165 @default.
• W2800280019 cites W4252972606 @default.
• W2800280019 cites W4317923381 @default.
• W2800280019 cites W79301660 @default.
• W2800280019 doi "https://doi.org/10.1159/000485384" @default.

• next